Friday, 6 November 2026European Markets

OL GROUPE Stock Went Down By Over 9% So Far On Monday

Loading stream...

entertainment and media company ol groupe (cac 40: olg.pa) appears to be experiencing difficulties in financial markets as its shares fell by 9.47% on monday morning at 11:05 est, dipping to eur1.87. this comes on the heels of a previous price increase but represents a significant drop as compared to the cac 40 index's negligible decrease of 0.23% after a prior session's increase.

ol groupe performance: a glance at the figures

ol groupe is best known for its management of the olympique lyonnais football club and the operations of groupama stadium. by the close of the last trading session, the company's shares stood at eur2.06, indicating a sharp 31.1% decline from the 52-week high of eur2.99. this sits significantly below its annual low value of eur2.10. as of now, the trailing twelve-month earnings per share (eps) for ol groupe is eur-1.4, further compounded by a drastic negative return on equity (roe) figure of -89.25%. this figure gives us an idea of the company's efficiency in generating returns relative to the equity shareholders have invested.

ol groupe revenue and share trading highlights

on a brighter note, ol groupe reported an impressive year-on-year quarterly revenue increase of 21.4%, amounting to eur176.55 million over twelve months. this uptick, however, appears to have been overshadowed by negative market sentiment, resulting in poor eps and roe numbers. looking at ol groupe shares, it becomes immediately apparent that their trading volume is low. on the first trading day of the week, the reported trading volume reached just 9,813, far below the daily average of 291,452. such scant trading volumes hint at a lack of interest among buyers and sellers, leading to thin trading which may increase volatility for the company's share prices.

more news about ol groupe (olg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com